Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics

被引:0
|
作者
Alyssa I. Clay-Gilmour
Shaji Kumar
S. Vincent Rajkumar
Abdul Rishi
Robert A. Kyle
Jerry A. Katzmann
David L. Murray
Aaron D. Norman
Alexandra J. Greenberg
Dirk R Larson
Megan M. O’Byrne
Susan L. Slager
Celine M. Vachon
机构
[1] Mayo Clinic,Department of Health Sciences Research
[2] Mayo Clinic,Division of Hematology
[3] Mercy Hospital,Department of Internal Medicine
[4] Mayo Clinic,Department of Laboratory Medicine and Pathology
来源
Leukemia | 2019年 / 33卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
We and others have shown increased risk of monoclonal gammopathy of undetermined significance (MGUS) in first-degree relatives of patients with multiple myeloma (MM). Whether familial risk of MGUS differs by the MM proband’s age at onset, tumor or clinical characteristics is unknown. MM and smoldering MM (SMM) cases (N = 430) were recruited from the Mayo Clinic in Rochester, Minnesota between 2005–2015. First-degree relatives over age 40 provided serum samples for evaluation of MGUS (N = 1179). Age and sex specific rates of MGUS among first-degree relatives were compared to a population-based sample. Cytogenetic subtypes were classified by Fluorescence in situ hybridization. MGUS was detected in 75 first-degree relatives for an age- and sex- adjusted prevalence of 5.8% (95% CI: 4.5–7.2). Prevalence of MGUS in first-degree relatives was 2.4 fold (95% CI: 1.9–2.9) greater than expected rates. Familial risk did not differ by proband’s age at diagnosis, gender, isotype, IgH translocation, or trisomy. This study confirms first-degree relatives of MM cases have a significantly higher risk of MGUS compared to the general population, regardless of age, gender, or tumor characteristics. In selected situations, such as multiple affected first-degree relatives, screening of first-degree relatives of MM cases could be considered for follow-up and prevention strategies.
引用
收藏
页码:499 / 507
页数:8
相关论文
共 50 条
  • [21] Clinical Characteristics and Risk Factors for Pleural Effusion in Patients with Multiple Myeloma
    Kang, Yu
    Hou, Zi-Liang
    Yang, Guang-Zhong
    Wang, Xiao-Juan
    Chen, Wen-Ming
    Shi, Huan-Zhong
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 : 649 - 657
  • [22] Genomic aberrations in monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) and the risk of progression to multiple myeloma (MM)
    Van Wier, S. A.
    Larson, D. M.
    Chng, W.
    Rempel, R.
    Ahmann, G. J.
    Henderson, K. M.
    Figueroa, G.
    Kyle, R. A.
    Rajkumar, S. V.
    Dispenzieri, A. D.
    Bersagel, P. L.
    Stewart, A. K.
    Therneau, T. M.
    Greipp, P. R.
    Fonseca, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 99 - 99
  • [23] Anthropometric characteristics and risk of multiple myeloma
    Blair, CK
    Cerhan, JR
    Folsom, AR
    Ross, JA
    EPIDEMIOLOGY, 2005, 16 (05) : 691 - 694
  • [24] Anthropometric Characteristics and Multiple Myeloma Risk
    Lu, Yani
    Sullivan-Halley, Jane
    Henderson, Katherine D.
    Ma, Huiyan
    Horn-Ross, Pamela L.
    Reynolds, Peggy
    Cress, Rosemary
    Bernstein, Leslie
    EPIDEMIOLOGY, 2010, 21 (02) : 272 - 273
  • [25] Tumor Lysis Syndrome in Multiple Myeloma: An Increasingly Recognized Risk—A Report of Seven Cases
    Abhijai Singh
    Shweta Gupta
    Barbara Yim
    Romy Thekkekara
    Indian Journal of Hematology and Blood Transfusion, 2017, 33 : 41 - 44
  • [26] Risk of Monoclonal Gammopathy of Undetermined Significance in First-Degree Relatives of Multiple Myeloma Cases By Cytogenetic Subtype
    Clay, Alyssa I.
    Rishi, Abdul
    Kumar, Shaji
    Rajkumar, S. Vincent
    Greenberg, Alexandra J.
    Larson, Dirk R.
    O'Byrne, Megan M.
    Slager, Susan L.
    Vachon, Celine M.
    BLOOD, 2016, 128 (22)
  • [27] Multiple Myeloma Patients With Prior Knowledge Of MGUS Have a Better Survival Compared To Multiple Myeloma Patients Without Prior Knowledge Of MGUS
    Sigurdardottir, Elin Edda
    Turesson, Ingemar
    Lund, Sigrun Helga
    Lindqvist, Ebba K.
    Korde, Neha
    Mailankody, Sham
    Bjoerkholm, Magnus
    Landgren, Ola
    Kristinsson, Sigurdur Y.
    BLOOD, 2013, 122 (21)
  • [28] Correlation of Agent Orange exposure, cytogenetics, and clinical outcomes in multiple myeloma and MGUS.
    Kulkarni, Pruthali
    Copeland, Laurel
    Hall, James Andy
    Dodlapati, Jyothi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] The molecular basis of the transition of MGUS to multiple myeloma.
    Davies, FE
    Dring, AM
    Cheng, L
    Rawstron, AC
    Shammas, M
    Hideshima, T
    Chauhan, D
    Tai, IT
    Auclair, D
    Robinson, E
    Wong, WH
    Munshi, NC
    Morgan, GJ
    Anderson, KC
    BLOOD, 2002, 100 (11) : 102A - 102A
  • [30] Plasmacytoid Dendritic Cells in Patients with MGUS and Multiple Myeloma
    Knight, Andrea
    Rihova, Lucie
    Kralova, Romana
    Penka, Miroslav
    Adam, Zdenek
    Pour, Ludek
    Piskacek, Martin
    Hajek, Roman
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (16)